Author:
Mhaidat N M,Zhang X D,Allen J,Avery-Kiejda K A,Scott R J,Hersey P
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM (2002) Multifaceted resistance of gliomas to temozolomide. Clinical Cancer Res 8: 2725–2734
2. Bossi G, Sacchi A (2007) Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 29: 272–284
3. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81: 1022–1030
4. Cozzi S, Parsons P, Ogbourne S, Pedley J, Boyle G (2006) Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res 66: 10083–10091
5. Culmsee C, Zhu X, Yu Q, Chan S, Camandola S, Guo Z, Greig N, Mattson M (2001) A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 77: 220–228
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献